Page 1,377«..1020..1,3761,3771,3781,379..1,3901,400..»

Knee Stem Cell Therapy & Platelet Rich Plasma

Posted: April 15, 2019 at 12:50 am

Have you been told that steroid injections or invasive surgery are your only options to treat your knee pain? Interventional orthopedics provides a non-surgical alternative that uses your body's own stem cells or blood platelets to help repair damage.

Recent research shows that some of the most popularorthopedic kneesurgeries,including meniscectomies, have no benefit and are nomore effective than placebo or sham surgery.

Moreover, knee replacement is extremely traumatic and carries associated risks, and even successful surgeries require months of painful rehab to regain strength and mobility. Most surgeries also accelerate degeneration, which leads toosteoarthritis and exacerbates the biomechanical problems that initially led to the need for the surgery.

Patients suffering from knee injuries or degenerative conditions should consider all of their options, including regenerative stem cell and platelet injection treatments.

At Regenexx we invented a new approach to orthopedic care we call Interventional Orthopedics. This approach involves the use of image guidance (flouroscopy and ultrasound) to precisely place high-dose stem cells or platelets from your body directly where they are needed in a specific joint structure.

These cells then work in the site of your injury to grow into new, healthy tissue, a process that will only occur if the cells have been placed exactly where they need to go in order to achieve positive outcomes for the patient.

This precise approach to orthopedic care cant be replicated by a surgeon or nurse in a chiropractors office. Interventional Orthopedics requires thousands of hours of training following a standardized protocol process to become a licensed Regenexx physician.

The innovative Regenexx procedures restore knee function and mobility and decrease pain without the need for surgery by regenerating damaged tissue. During this outpatient procedure, ourexpert physiciansuseprecise image guidanceto inject custom concentrations ofyour body's natural healing agentsinto the exact areas of damage to tighten and stabilize your knee joint for better function and mobility.

This page contains an extensive library of educational resources on kneeconditions and our patented Regenexx kneeprocedures. We encourage you to research your options.

GET RELIEF. 855-330-5818

Read more:
Knee Stem Cell Therapy & Platelet Rich Plasma

Posted in Stem Cell Therapy | Comments Off on Knee Stem Cell Therapy & Platelet Rich Plasma

Stem Cell Therapy FAQS | National Stem Cell Centers

Posted: April 15, 2019 at 12:50 am

Broadly speaking, there are two basic kinds of stem cells: embryonic stem cells and adult stem cells. As the name implies, embryonic stem cells come from embryos. These kinds of cells are known as pluri-potential, meaning that they can become anything required to create a human body. Embryonic stem cells are taken from unwanted embryos, and as such, are highly controversial. Embryonic stem cell use is highly regulated and has also been associated with certain kinds of tumor formation.

Adult stem cells, on the other hand, come from adults. Adult stem cells are harder to isolate, but still retain many (but not all) of their undifferentiated properties, allowing them to become nerve, skin, bone, cartilage and other tissues as needed, depending on the specific type of tissue they are recovered from. Bone marrow adult stem cells (mesenchymal stem cells), for instance, come from the mesodermal sections of the human body and can form into cartilage and bone.

Evidence suggests that they are also capable of differentiating into other tissues like connective tissues (ligaments, muscle, tendons), blood vessels, fatty tissues, nerve and blood vessels. Bone marrow stem cells are not as prevalent in the body and usually need to be cultured (encouraged to multiply in the lab) so that there are enough to work with.

Fortunately, human fat cells also have mesenchymal stem cells (MSCs) which can be more easily harvested and separated from fat cells for use. Because the ratio of mesenchymal stem cells (MSCs) is over a thousand times greater in fat cells than bone marrow, these usually do not need to be cultured and can be obtained from fatty deposits in the patients body.

Here is the original post:
Stem Cell Therapy FAQS | National Stem Cell Centers

Posted in Stem Cell Therapy | Comments Off on Stem Cell Therapy FAQS | National Stem Cell Centers

Our Team – Neural Stem Cell Institute, Rensselaer NY

Posted: April 12, 2019 at 11:51 pm

Our Team

Working together to discover cures. Dr. Sally Temple

Christina Allen-Calabrese, Ph.D. Research Scientist

Dr. Christina Allen-Calabrese obtained a Ph.D. from the University at Albany School of Public Health in partnership with the New York State Department of Health in Biomedical Science with formal training in neuroscience. Dr. Calabrese is trained in mouse and human neural stem cell research. She also has extensive experience in Biosafety Level 2 and 3 Laboratories and GLP training. Dr. Calabrese currently studies the role of the meninges in providing specific factors to different regions of the brain and is exploring the hypothesis that perturbations in this system could contribute to neurodegenerative diseases, such as Alzheimers and Parkinsons disease.

Nathan Boles, Ph.D. Principal Investigator

Ph.D. Interdepartmental Program in Cell and Molecular Biology, Baylor College of Medicine.

Dr. Boles carried out his thesis work with Dr. Margaret A. Goodell studying the regulation of the hematopoietic stem cell. His work at NSCI explores the role of epigenetics in neural stem cell self-renewal and differentiation.More about Nathan.

Sue Borden, B.A. Research Technician

BA Biology: Russell Sage College, Biotechnology Certificate: HVCC

Sue has worked in neurobiology research labs at SUNYA, AMC and Cornell University, in clinical labs in Ithaca and the Albany area and as a teaching assistant in a local K-12 school. She recently joined the Retinal Stem Cell Consortium team as a research technician. Sue will be culturing and analyzing hRPE stem cells in preparation for clinical trials in the treatment of AMD.

David Butler, Ph.D. Principal Investigator

Dr. Butlers long-term goal is to develop novel intracellular antibody (intrabody) therapeutics forneurodegenerative disorders caused by misfolded proteins. He hasa broad background in degenerative diseases associated with aging. As a postdoc in the Messer lab, whichpioneeredthe use of intracellular antibodies in the brain, David developed bifunctional intra-cellular antibodies. Davids bifunctional antibodies were able to prevent mutant Huntingtin and Synuclein from misfolding while directing them to the proteasome for degradation. He is currently utilizing induced pluripotent stem cell (iPSC) disease modeling to develop novel bifunctional intrabody reagents for tauopathies such as FTD and Alzheimers disease. Dr. Butler is also an Adjunct Professor in the Biomedical Sciences Department, School of Public Health, SUNY Albany.More about David.

Carol Charniga, B.S. Research Technician/Manager of Operations

Carol worked in cancer research labs in Pennsylvania and at Albany Medical Center before joining AMCs Dept. of Neurosurgery and Neuroscience and the lab of Dr. Sally Temple. Since the creation of the Neural Stem Cell Institute, Carol has been involved in all projects developing CNS, spinal cord and eye as well as being the safety officer and Lab Manager of Operations. Currently, most of her workday is spent in the eye group lab, involved in the macular degeneration program.

Rebecca Chowdhury, Ph.D. Post Doctoral Fellow

Dr. Chowdhury obtained her Ph.D. from Iowa State University, studying intrinsic factors that control cell fate decisions in the developing retina. She is currently studying the role of Stau2,an RNA-binding protein (RBP) involved in neuronal development andmaturation. She isusing human induced pluripotent stem cell-derived cortical neurons and a genetically modified mouse model in her studies.More about Rebecca.

Liz Fisher, Ph.D. Post Doctoral Fellow

Dr. Fisherobtained her Ph.D. from the University of Texas Health Science Center at San Antonio, UT, studying the role of astrocyte glutamate metabolism following stroke. She then boldly made the decision to leave the warmth of south Texas for upstate New York in October 2017. As a post-doctoral fellow at the Neural Stem Cell Institute,Lizcontinues to study the roles of non-neuronal cells following injury. She is currently investigating how modulating immune cell populations using biodegradable microbeads can influence recovery following spinal cord injury.More about Liz.

Susan K. Goderie, A.A.S., B.S. Research Technician/ Manager of Research

After attending Hudson Valley Community College and Plattsburg State University, Susan worked for the New York State Birth Defects Institute culturing lymphocytes for karyology. Later she worked in the kidney transplantation lab at the Albany Medical Center. She worked with Dr. Harold Kimelberg studying astrocytic swelling in response to ischemic conditions until 1995 when she joined the lab of Dr. Sally Temple. She oversees the daily lab research; training of new faculty, staff, and students; supervising the technical staff as well as directly contributing to the spinal cord injury, stem cell niche, embryonic brain development, and macular degeneration projects.

Shona Joy, Ph.D. Post Doctoral Fellow

Dr. Joy holds two masters degree in Stem Cell Technology and Biotechnology and a Ph.D. in Stem Cells Neuroscience fromCardiff University, UK. She is interested in using pluripotent stem cells to generate models for neurodegenerative diseases(Alzheimers disease and Progressive supranuclear palsy) to facilitate regenerative medicine and drug discovery. She uses the stable induced pluripotent stem cell lines she generates to investigate the signaling pathways involved in reprogramming these cells.More about Shona.

Thomas Kiehl, Ph.D. Principal Investigator

Dr. Kiehl started his career with an M.S. in Computer Science from Rensselaer Polytechnic Institute. After 11 years at GE Global Research, in their Computational Intelligence Lab, Tom returned to RPI full time to pursue a Ph.D. in Multidisciplinary Science with a focus on systems biology and biotechnology. This was followed by a postdoc at Albany Medical College in Immunology. A Computing Innovation Fellowship, awarded by the Computing Research Association, allowed Tom to spend two years at the SUNY College of Nanoscale Science and Engineering where he began work in computational neuroscience and RNA-seq analysis. At NSCI Dr. Kiehl facilitates the integration of data analysis with bench work. Tom is also pursuing applications of high-throughput in-vitro electrophysiological platforms for the study of development, spinal cord injury, and neurological disease mechanisms. Learn more about the role of Computing@NSCI.More about Tom.

Steven Lotz, B.S.Research Technician

After college, Steve worked for Taconics Surgical Modifications Department. In 2001, he began a career as a Research Technician at the Albany Medical Center. Three years later, he joined AMCs Immunology Core as the FACS operator. In 2009 he began working at NeuraCell Bank, part of the Neural Stem Cell Institute, as the Sr. Flow Cytometry Applications Specialist.

Natalia Lowry, M.D., Ph.D. Principal Investigator

Dr. Lowry received her MD from Russian State Medical University and her Ph.D. from Albany Medical College in 2000.Dr. Lowry has been trained in mouse neural stem cell research during a post-doctoral fellowship under Dr. Sally Temple, and then joined NSCI in 2007 as aprincipalinvestigator with interest in using neural stem cells as a therapeutic tool to treat spinal cord injuries and other neurodegenerative diseases. Currently, Dr. Lowry combines her research work at NSCI with a clinical education position at

Anne Messer, Ph.D. Principal Investigator

Anne Messer, Ph.D., is a senior scientist focused on the development of novel therapeutics for degenerative diseases caused by misfolded proteins that trigger breakdowns in the functions of critical cells. She pioneered the use of engineered antibody technologies for Huntingtons and Parkinsons disease. Her recent studies range from antibodyengineering and nanobody selection to brain delivery using gene therapies. This biotechnology to harness immune processes now is being combined with stem cell studies and expanded to cover a range of important age-related diseases, including Age-relatedMacular Degeneration. More about Anne.

Khadijah Onanuga, Ph.D., PMP Director of Research Programs

Dr. Onanuga received her Ph.D.in Nanoscale Engineering with a specialty in Nanobiotechnology from the SUNY Polytechnic Institute, Colleges of Nanoscale Science and Engineering. As the Director of Research Programs at NSCI, Dr. Onanuga oversees the research programs at the institute which include: the Age-Related Macular Degeneration Program of theRetinal Stem Cell Consortium, its IND application process for a cell-based therapy, the Stem Cell Group of the Tau Consortium- a group dedicated to using stem cell technology for research and drug discovery that targets neurodegenerative diseases, and other programs.

Natasha Rugenstein, A.S.Research Technician

Tashaattended Hudson Valley Community College, NY, receiving an A.S. degree in biological sciences and the Biotechnology Certificate. She joined the Neural Stem Cell Institute in 2017, and currently works on the histology of study samples in on-going projects while continuing her education in biology.

Jeffrey Stern, M.D., Ph.D. Principal Investigator/ Director of Translational Research/ Co-Founder

Dr. Stern was trained as a biophysicist in vision research at Brandeis University, MA and Rockefeller University, NY, receiving his Ph.D. in 1982. He then studied medicine at the University of Miami Medical School and completed his residency in Ophthalmology at the Albany Medical Center. Dr. Stern did a fellowship in vitreo-retinal specialty at Mt. Sinai Medical School, NYC.More about Dr. Stern.

Sally Temple, Ph.D. Scientific Director/ Principal Investigator/ Co-Founder

Dr. Sally Temple is the co-Founder and Scientific Director of the Neural Stem Cell Institute located in Rensselaer, NY. A native of York, England, Dr. Temple leads a team of 30 researchers focused on using neural stem cells to develop therapies for eye, brain, and spinal cord disorders. In 2008, she was awarded the MacArthur Fellowship Award for her contribution and future potential in the neural stem cell field. As the Scientific Director of NSCI, Dr. Temple oversees the research mission from basic to translational projects. She is also responsible for the staff, budget, and developing the overall strategic plan for the institute. Dr. Temple is a member of the board of directors of the International Society for Stem Cell Research and of the medical advisory boards of the NY Stem Cell Foundation and the Genetics Policy Institute. Her numerous articles have been published in such journals asNature,Cell Stem Cell,Neuron,andCell.More about Sally.

Brian Unruh, B.S. Research Technician

Brian graduated from Binghamton University in 2017 and joined the NSCI shortly thereafter. His work focuses chiefly on the production, characterization, and purification of iPSC derived retinal pigment epithelial cells, as well as age-related macular degeneration disease modeling. Brian aspires to attend medical school in the nearest future.

Jenny Yue Wang, M.D. Research Technician

Jenny obtained an MD in China and worked in the University of California before joining Dr. Sally Temples lab. Her research interest and experiences include but are not limited to neural stem cell fate choice, cell culture and in vivo experiments on mice.

Xiuli Zhao, M.D., Ph.D. Post Doctoral Fellow

Dr. Zhao earned her MD from the Anhui University of Chinese Medicine and completed her training as an ophthalmologist in the first affiliated hospital of Jinan University, China. She received her Ph.D. in Neuroscience from Arizona State University in 2017. Her current research involves live cell imaging to compare neural stem cell (NSC) activity changes in the subventricular zone between young and aged mice. She is also working to identify the choroid plexus-secreted environment factors that alter mouse and human NSC activities with aging.More about Xiuli.

Cindy Butler Executive Assistant

Cindy is the go toperson at our organization. She has many years of experience handling the administrative tasks associated with running a research laboratory. Perhaps it is her previous experience in childcare that enables her to remain pleasant in even the most difficult situations.

Jake Parks Bookkeeper

Jake is responsible for the recording of data transactions into the financial accounting system and retaining the documentation for those records. Jake also supports the IT department as a first responder on the help desk and assists with the maintenance of the Institutes computer network.

Tom Irwin Administrative Director

Tom received his MBA from Bernard Baruch College City University of New York. He has worked in the academic medical environment for 30 plus years mostly in research administration at Cornell Medical College, NYC and Albany Medical College, Albany, NY. He has also served as an administrative reviewer for the NIH, IACUC institutional official, has been an institutional biosafety committee member and is currently an ex-officio member of the RPI Institutional Stem Cell Research Oversight committee (ISCRO).

The rest is here:
Our Team - Neural Stem Cell Institute, Rensselaer NY

Posted in Iowa Stem Cells | Comments Off on Our Team – Neural Stem Cell Institute, Rensselaer NY

Transhumanist politics – Wikipedia

Posted: April 12, 2019 at 11:50 pm

Transhumanist politics constitutes a group of political ideologies that generally express the belief in improving human individuals through science and technology.

The term "transhumanism" with its present meaning was popularised by Julian Huxley's 1957 essay of that name.[1]

Natasha Vita-More was elected as a Councilperson for the 28th Senatorial District of Los Angeles in 1992. She ran with the Green Party, but on a personal platform of "transhumanism". She quit after a year, saying her party was "too neurotically geared toward environmentalism".[2][3]

James Hughes identifies the "neoliberal" Extropy Institute, founded by philosopher Max More and developed in the 1990s, as the first organized advocates for transhumanism. And he identifies the late-1990s formation of the World Transhumanist Association (WTA), a European organization which later was renamed to Humanity+ (H+), as partly a reaction to the free market perspective of the "Extropians". Per Hughes, "[t]he WTA included both social democrats and neoliberals around a liberal democratic definition of transhumanism, codified in the Transhumanist Declaration."[4][5] Hughes has also detailed the political currents in transhumanism, particularly the shift around 2009 from socialist transhumanism to libertarian and anarcho-capitalist transhumanism.[5] He claims that the left was pushed out of the World Transhumanist Association Board of Directors, and that libertarians and Singularitarians have secured a hegemony in the transhumanism community with help from Peter Thiel, but Hughes remains optimistic about a techno-progressive future.[5]

In 2012, the Longevity Party, a movement described as "100% transhumanist" by cofounder Maria Konovalenko,[6] began to organize in Russia for building a balloted political party.[7] Another Russian programme, the 2045 Initiative was founded in 2012 by billionaire Dmitry Itskov with its own "Evolution 2045" political party advocating life extension and android avatars.[8][9]

Writing for H+ Magazine in July 2014, futurist Peter Rothman called Gabriel Rothblatt "very possibly the first openly transhumanist political candidate in the United States" when he ran as a candidate for the United States Congress.[10]

In October 2014, Zoltan Istvan announced that he would be running in the 2016 United States presidential election under the banner of the "Transhumanist Party."[11] By May 2018, the Party had nearly 880 members, and chairmanship had been given to Gennady Stolyarov II.[12] Other groups using the name "Transhumanist Party" exist in the United Kingdom[13][14][15] and Germany.[16]

According to a 2006 study by the European Parliament, transhumanism is the political expression of the ideology that technology should be used to enhance human abilities.[17]

According to Amon Twyman of the Institute for Ethics and Emerging Technologies (IEET), political philosophies which support transhumanism include social futurism, techno-progressivism, techno-libertarianism, and anarcho-transhumanism.[18] Twyman considers such philosophies to collectively constitute political transhumanism.[18]

Techno-progressives also known as Democratic transhumanists,[19][20] support equal access to human enhancement technologies in order to promote social equality and prevent technologies from furthering the divide among socioeconomic classes.[21] However, libertarian transhumanist Ronald Bailey is critical of the democratic transhumanism described by James Hughes.[22][23] Jeffrey Bishop wrote that the disagreements among transhumanists regarding individual and community rights is "precisely the tension that philosophical liberalism historically tried to negotiate," but that disagreeing entirely with a posthuman future is a disagreement with the right to choose what humanity will become.[24] Woody Evans has supported placing posthuman rights in a continuum with animal rights and human rights.[25]

Riccardo Campa wrote that transhumanism can be coupled with many different political, philosophical, and religious views, and that this diversity can be an asset so long as transhumanists do not give priority to existing affiliations over membership with organized transhumanism.[26]

Some transhumanists question the use of politicizing transhumanism.[who?] Truman Chen of the Stanford Political Journal considers many transhumanist ideals to be anti-political.[27]

Democratic transhumanism, a term coined by James Hughes in 2002, refers to the stance of transhumanists (advocates for the development and use of human enhancement technologies) who espouse liberal, social, and/or radical democratic political views.[28][29][30][31]

According to Hughes, the ideology "stems from the assertion that human beings will generally be happier when they take rational control of the natural and social forces that control their lives."[29][32]The ethical foundation of democratic transhumanism rests upon rule utilitarianism and non-anthropocentric personhood theory.[33] Democratic transhumanist support equal access to human enhancement technologies in order to promote social equality and to prevent technologies from furthering the divide among the socioeconomic classes.[34]While raising objections both to right-wing and left-wing bioconservatism, and libertarian transhumanism, Hughes aims to encourage democratic transhumanists and their potential progressive allies to unite as a new social movement and influence biopolitical public policy.[29][31]

An attempt to expand the middle ground between technorealism and techno-utopianism, democratic transhumanism can be seen as a radical form of techno-progressivism.[35] Appearing several times in Hughes' work, the term "radical" (from Latin rdx, rdc-, root) is used as an adjective meaning of or pertaining to the root or going to the root. His central thesis is that emerging technologies and radical democracy can help citizens overcome some of the root causes of inequalities of power.[29]

According to Hughes, the terms techno-progressivism and democratic transhumanism both refer to the same set of Enlightenment values and principles; however, the term technoprogressive has replaced the use of the word democratic transhumanism.[36][37]

Hughes has identified 15 "left futurist" or "left techno-utopian" trends and projects that could be incorporated into democratic transhumanism:

These are notable individuals who have identified themselves, or have been identified by Hughes, as advocates of democratic transhumanism:[38]

Science journalist Ronald Bailey wrote a review of Citizen Cyborg in his online column for Reason magazine in which he offered a critique of democratic transhumanism and a defense of libertarian transhumanism.[22][23]

Critical theorist Dale Carrico defended democratic transhumanism from Bailey's criticism.[39] However, he would later criticize democratic transhumanism himself on technoprogressive grounds.[40]

Libertarian transhumanism is a political ideology synthesizing libertarianism and transhumanism.[28][41][42]Self-identified libertarian transhumanists, such as Ronald Bailey of Reason magazine and Glenn Reynolds of Instapundit, are advocates of the asserted "right to human enhancement" who argue that the free market is the best guarantor of this right, claiming that it produces greater prosperity and personal freedom than other economic systems.[43][44]

Libertarian transhumanists believe that the principle of self-ownership is the most fundamental idea from which both libertarianism and transhumanism stem. They are rational egoists and ethical egoists who embrace the prospect of using emerging technologies to enhance human capacities, which they believe stems from the self-interested application of reason and will in the context of the individual freedom to achieve a posthuman state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity. They extend this rational and ethical egoism to advocate a form of "biolibertarianism".[43]

As strong civil libertarians, libertarian transhumanists hold that any attempt to limit or suppress the asserted right to human enhancement is a violation of civil rights and civil liberties. However, as strong economic libertarians, they also reject proposed public policies of government-regulated and -insured human enhancement technologies, which are advocated by democratic transhumanists, because they fear that any state intervention will steer or limit their choices.[45][46][23]

Extropianism, the earliest current of transhumanist thought defined in 1988 by philosopher Max More, initially included an anarcho-capitalist interpretation of the concept of "spontaneous order" in its principles, which states that a free market economy achieves a more efficient allocation of societal resources than any planned or mixed economy could achieve. In 2000, while revising the principles of Extropy, More seemed to be abandoning libertarianism in favor of modern liberalism and anticipatory democracy. However, many Extropians remained libertarian transhumanists.[28]

Critiques of the techno-utopianism of libertarian transhumanists from progressive cultural critics include Richard Barbrook and Andy Cameron's 1995 essay The Californian Ideology; Mark Dery's 1996 book Escape Velocity: Cyberculture at the End of the Century; and Paulina Borsook's 2000 book Cyberselfish: A Critical Romp Through the Terribly Libertarian Culture of High-Tech.

Barbrook argues that libertarian transhumanists are proponents of the Californian Ideology who embrace the goal of reactionary modernism: economic growth without social mobility.[47] According to Barbrook, libertarian transhumanists are unwittingly appropriating the theoretical legacy of Stalinist communism by substituting, among other concepts, the "vanguard party" with the "digerati", and the "new Soviet man" with the "posthuman".[48] Dery coined the dismissive phrase "body-loathing" to describe the attitude of libertarian transhumanists and those in the cyberculture who want to escape from their "meat puppet" through mind uploading into cyberspace.[49] Borsook asserts that libertarian transhumanists indulge in a subculture of selfishness, elitism, and escapism.[50]

Sociologist James Hughes is the most militant critic of libertarian transhumanism. While articulating "democratic transhumanism" as a sociopolitical program in his 2004 book Citizen Cyborg,[31] Hughes sought to convince libertarian transhumanists to embrace social democracy by arguing that:

Klaus-Gerd Giesen, a German political scientist specializing in the philosophy of technology, wrote a critique of the libertarianism he imputes to all transhumanists. While pointing out that the works of Austrian School economist Friedrich Hayek figure in practically all of the recommended reading lists of Extropians, he argues that transhumanists, convinced of the sole virtues of the free market, advocate an unabashed inegalitarianism and merciless meritocracy which can be reduced in reality to a biological fetish. He is especially critical of their promotion of a science-fictional liberal eugenics, virulently opposed to any political regulation of human genetics, where the consumerist model presides over their ideology. Giesen concludes that the despair of finding social and political solutions to today's sociopolitical problems incites transhumanists to reduce everything to the hereditary gene, as a fantasy of omnipotence to be found within the individual, even if it means transforming the subject (human) to a new draft (posthuman).[51]

Read more from the original source:
Transhumanist politics - Wikipedia

Posted in Transhumanist | Comments Off on Transhumanist politics – Wikipedia

Stem Cell Therapy for Joint Pain and Soft Tissue, Colorado

Posted: April 12, 2019 at 11:50 pm

We use adipose-derived stem cells, which are harvested from the patients abdominal fat reserves our bodys richest source of mesenchymal adult stem cells. We also harvest stem cells from bone marrow to provide an additional cornucopia of regenerative cells. Although bone marrow has up to 1,000 times fewer stem cells per volume than fat, its unique growth factors and significant hematopoietic cells additional help to drive tissue regeneration.

By utilizing the combination of these biologic solutions, we maximize the healing potential from an autologous stem cell procedure.Once we have isolated the specific stem cells, they are then injected into the specific area of damage using real-time x-ray (fluoroscopic)or ultrasound guidance.

At this time, we also introduce a PRP injection (platelet-rich plasma) to further the growth and differentiation of these cells. Once there, these regenerative cells have the potential to dramatically reduce inflammation, encourage new vascularity and stimulate the body to repair and replace tissue that has deterioratedover time or been traumatized from injury or overuse.

Four weeks after the initial stem cell injection, a second injection of platelet rich plasma (PRP)or bone marrow concentrate is performed to enhance the regenerative process.For more details, please visit our page dedicated to thestem cell therapy procedure.

Whether the damagedarea is the result of a traumatic sports injury or the product of daily wear and tear (osteoarthritis), stem cell therapy for joints and soft tissue may offer a powerful solution to resolving the ongoing discomfort. Both long standing and more newly acquired injuries have the potential to benefit from this state-of-the-art treatment.

ThriveMDs newest biologic treatment, Alpha 2 macroglobulin (A2M), is proving to be an excellent complimentary treatment to our regenerative stem cell procedures. Scientific evidence points to A2M being the key to stopping arthritis at the molecular level. A2M is a Broad Spectrum Multi-Purpose Protease Inhibitor that captures and inactivates the three major chemicals that lead to joint breakdown and cartilage damage.

Read the original:
Stem Cell Therapy for Joint Pain and Soft Tissue, Colorado

Posted in Colorado Stem Cells | Comments Off on Stem Cell Therapy for Joint Pain and Soft Tissue, Colorado

4 Gene Therapy Players Likely to Become Buyout Targets in 2019

Posted: April 12, 2019 at 11:49 pm

The biotech industry has had a good start in 2019. The Zacks Biomed and Genetics industry has gained 16.1%, outperforming the broader S&P 500, which is up 15.3%, so far in 2019. The rise in merger and acquisitions (M&A) activity this year is one of the major driving forces behind this rally. The biotech industry is ranked 86 among the 256 Zacks industries.

Several large-cap pharma companies are facing patent expirations of their major drugs and pricing challenges in the U.S. market. This has led to consolidation through M&A in the pharma space. In a landmark deal, Bristol-Myers has offered to acquire big biotech, Celgene, for $74 billion. The large-cap companies are looking to acquire or partner with smaller biotech companies to boost their pipeline with newer technologies. Acquisitions, which are done generally by giving a premium on current price, and partnerships, which provide funds to smaller companies to support continued development of pipeline candidates, boost the stock price of the target companies.

A few of the M&A deals so far in 2019 involve companies with promising gene therapy candidates. Gene therapy, a new wave of innovation in pharma space, enables to mitigate the adverse effects of a malfunctioning disease-causing gene. These therapies have a different approach from traditional drug therapies as the underlying cause can be treated instead of the symptoms. These therapies generally target rare indications including hemophilia, Duchenne muscular dystrophy (DMD) and Parkinson's disease among others, which will likely lead to higher price realization. The gene therapy segment is expected to attract a lot more attention from pharma players going forward. Better efficacy achieved by gene therapies in clinical studies and likely rise in involvement of pharma companies may lead to higher M&A activity in the gene therapy segment.

In 2018, Novartis acquired AveXis for its gene therapy candidates and Celgene acquired Juno Therapeutics to add CAR T-cell therapy for cancer. In 2019, Roche and Biogen offered to buy Spark Therapeutics ONCE and Nightstar Therapeutics NITE, respectively. Both Spark and Nightstar are developing gene therapies targeting rare indications. Pfizer collaborated with innovative gene therapy developer Vivet Therapeutics, a privately-held company. There are several companies in the biotech industry, which are developing gene therapy candidates or shifting their focus to developing similar therapies. Looking at this trend, we expect some more deals targeting gene therapy makers.

We present four companies with promising gene therapy candidates in their pipelines. These companies may become acquisition targets going forward.

uniQure N.V. QURE)

The company is a promising player in the space. It is engaged in creating a pipeline of innovative gene therapies that have been developed both internally and through its collaboration, focused on cardiovascular diseases, with Bristol Myers-Squibb.

The companys lead candidate AMT-061, an experimental AAV5-based gene therapy incorporating the FIX-Padua variant, is being evaluated in the phase III HOPE-B pivotal study for the treatment of patients with severe and moderately severe hemophilia B. In January 2019, the company received clearance from the FDA to initiate clinical study for AMT-130 for the treatment of Huntingtons disease.

Story continues

uniQures stock has moved up 115.4% so far this year against the industrys decline. The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here.

Audentes Therapeutics BOLD)

It is another biotechnology company with a pipeline of innovative gene therapy products for patients living with rare diseases. The company is currently conducting phase I/II studies for its lead product candidates, AT132,for the treatment of X-linked myotubular myopathy (XLMTM), and AT342 for the treatment of Crigler-Najjar syndrome. The company currently has two additional product candidates in its pipeline, AT845 for the treatment of Pompe disease and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia (CASQ2-CPVT), which are likely to enter clinical development.

Audentes currently carries a Zacks Rank #3. Shares have gained 82.9% year to date.

REGENXBIO Inc. RGNX)

The company is a clinical-stage biotechnology company that focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. The companys most advanced candidate, RGX-314, is being evaluated in a phase I/IIa for treating wet age-related macular degeneration (AMD). The company is planning to initiate a mid-stage study on the candidate for treating an additional chronic retinal condition in the second half of 2019. Apart from RGX-314, the company is also developing three other gene therapy candidates for treating certain rare neurological symptoms.

REGENXBIO currently carries a Zacks Rank #3. So far this year, shares have gained 41.3%.

Solid Biosciences Inc. SLDB)

The companys lead product candidate is SGT-001, a microdystrophin gene therapy that is in phase I/II clinical studies, intended to restore functional dystrophin protein expression in DMD patients.

Solid Biosciences currently carries a Zacks Rank #3.

Solid Biosciences Inc. Price

Solid Biosciences Inc. Price | Solid Biosciences Inc. Quote

Some other companies with gene therapy candidates in their pipeline include Sarepta Therapeutics SRPT and Ophthotech OPHT, which are developing treatments for DMD and retinal disorder, respectively.

Whats Ahead?

Investors should keep an eye on this space as potential approvals and data read-outs from late-stage studies on several candidates are likely to drive the related stocks.

Is Your Investment Advisor Fumbling Your Financial Future?

See how you can more effectively safeguard your retirement with a new Special Report, 4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.

Click to get it free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportOphthotech Corporation (OPHT) : Free Stock Analysis ReportuniQure N.V. (QURE) : Free Stock Analysis ReportSpark Therapeutics, Inc. (ONCE) : Free Stock Analysis ReportREGENXBIO Inc. (RGNX) : Free Stock Analysis ReportSarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis ReportNightstar Therapeutics PLC Sponsored ADR (NITE) : Free Stock Analysis ReportAudentes Therapeutics, Inc. (BOLD) : Free Stock Analysis ReportSolid Biosciences Inc. (SLDB) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Excerpt from:
4 Gene Therapy Players Likely to Become Buyout Targets in 2019

Posted in Gene therapy | Comments Off on 4 Gene Therapy Players Likely to Become Buyout Targets in 2019

Chronic variable stress activates hematopoietic stem cells …

Posted: April 12, 2019 at 8:50 am

Clinical study.

The clinical study titled 'Effects of Socioenvironmental Stress on the Human Hematopoietic System' was an open, monocenter, single-arm study that enrolled medical residents working on the intensive care unit at University Hospital, Freiburg, Germany. This study was registered with the German Registry for Clinical Studies (DRKS00004821) and was approved by the Ethics Committee of Albert-Ludwigs-University Freiburg, Germany (No. 52/13). All residents working on the ICU were considered eligible to participate in the study. Exclusion criteria were smoking, any acute or chronic illness, regular intake of medication or failure to consent. Twenty-nine volunteers (23 male, 6 female, mean age 33.7 0.8 years) were enrolled after signing the informed consent form. Residents gave two blood samples (baseline and stress). The off-duty sample (baseline) was collected after 10 0.9 consecutive days off duty. The on-duty sample (stress) was collected after 7 0.3 consecutive days of ICU duty. A subcohort of participants completed the Perceived Stress Scale 10-item inventory5 before starting to work on the ICU (baseline), as well as after several weeks on duty (stress). Short-term perception for stress frequency and intensity was measured with visual analog scales (scale 010)6, which each participant completed at the time of the blood sampling. The mean circadian time difference between the baseline and the stress sample was 20 15.9 min. Blood samples were analyzed in a blinded fashion at the routine clinical laboratory of the University Hospital, Freiburg, Germany.

We used C57BL/6, CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ), UBC-GFP (C57BL/6-Tg(UBC-GFP)30Scha/J), Apoe/ (B6.129P2-Apoetm1Unc/J), TH-Cre (B6.Cg-Tg(Th-Cre)1Tmd/J) and iDTR (C57BL/6-Gt(ROSA)26Sortm1(HBEGF)Awai/J) mice, all female and 1012 weeks of age (Jackson Laboratories, Bar Harbor, ME). Adrb3/ mice16 were donated by P. Frenette (Albert Einstein College of Medicine, New York, NY, USA) and B. Lowell (Beth Israel Deaconess Medical Center, Boston, MA, USA). Nestin-GFP mice41 were a gift from G. Enikolopov (Cold Spring Harbor Laboratory, NY). All procedures were approved by the Subcommittee on Animal Research Care at Massachusetts General Hospital. For each experiment, age-matched female littermates were randomly allocated to study groups. Animal studies were performed without blinding of the investigator.

Mice were exposed to socioenvironmental stressors7,8,9 for one or three weeks in C57BL/6 mice or six weeks in Apoe/ mice. Stress procedures were performed between 7 a.m. and 6 p.m. The following stressors were applied. For cage tilt, the cage was tilted at a 45 angle and kept in this position for six hours. For isolation, mice were individually housed in an area one-quarter of the original cage size (12 cm 8 cm) for four hours, followed by crowding, during which 10 animals were housed in one cage for two hours. Mice were monitored during the crowding procedure, and 'fighters' were separated. For damp bedding, water was added to the cage to moisten the bedding without generating large pools. Mice were kept for six hours with damp bedding. For rapid light-dark changes, using an automatic timer, the light was switched with an interval of seven minutes for two hours. For overnight illumination, mice were housed in a separate room with illumination from 7 p.m. to 7 a.m. All stressors were randomly shuffled in consecutive weeks. Efficacy of the chronic stress procedures was confirmed by measurement of blood corticosterone levels (Supplementary Fig. 12c).

Mice were irradiated using a split dose of 2 600 cGy with an interval of 3 h between doses. Animals were irradiated 12 h before bone marrow reconstitution.

For competitive bone marrow repopulation assays42, we co-transferred 2 106 whole bone marrow cells from CD45.1 mice after three weeks of stress or from nonstressed controls together with equal cell numbers of CD45.2 competitor cells from nonstressed wild-type mice into lethally irradiated UBC-GFP CD45.2 mice. Engraftment was assessed by comparing blood leukocyte chimerism for CD45.1 cells between groups after 2, 3 and 4 months. For limiting dilution experiments42, donor doses of 1.5 104, 6 104, 12.5 104 or 5 105 whole bone marrow cells from CD45.1 mice after three weeks of stress or from nonstressed controls were co-transferred with 5 105 CD45.2 competitor cells into lethally irradiated CD45.2 recipients. Engraftment was assessed after four months as at least >0.1% multilineage blood chimerism for B lymphocytes, T lymphocytes and myeloid lineage cells derived from donor bone marrow. Poisson's statistic was calculated using L-calc software (Stemcell Technologies) and ELDA software43. Bone marrow of two mice was pooled for each cell population.

To inhibit 3-adrenergic signaling, a specific antagonist for the 3-adrenergic receptor (SR 59230A, Sigma-Aldrich) was injected at 5 mg/kg body weight i.p. twice per day44. For inhibition of 2-adrenergic signaling, ICI118,551 hydrochloride (Sigma-Aldrich) was injected daily at a dose of 1 mg/kg body weight i.p. (ref. 18) for three weeks. The control groups received saline injections.

TH-Cre mice were cross-bred with iDTR mice. 1012 week old female TH-iDTR mice were intraperitoneally injected with 0.1 g/kg body weight diphtheria toxin (DT) on day 0 and day 3 after initiation of stress procedures18. Age-matched littermates (TH-Cre, iDTR or WT) that were also stressed and injected with DT served as controls.

Nonstressed mice and mice that had been stressed for three weeks were injected intravenously with 150 mg/kg body weight 5-FU (Sigma)45 on day 0. Mice were then followed over the course of 21 days, and the absolute number of blood leukocytes was measured after 7, 14 and 21 days. Stress exposure continued for the remaining 3 weeks after 5-FU exposure.

Flushed bone marrow was passed through a 40-m cell strainer and collected in PBS containing 0.5% BSA and 1% FBS (FACS buffer). Aortas were excised, minced and digested in collagenase I (450 U/ml), collagenase XI (125 U/ml), DNase I (60 U/ml) and hyaluronidase (60 U/ml) (all Sigma-Aldrich) at 37 C at 750 r.p.m. for 1 h. For sorting niche cells, bones were harvested from nestin-GFP mice. Bone marrow endothelial cells (ECs) and mesenchymal stem cells (MSCs) were obtained by flushing out bone marrow, which was then digested in 10 mg/ml collagenase type IV (Worthington) and 20 U/ml DNase I (Sigma)46. For obtaining bone osteoblastic lineage cells, we crushed bones, washed off residual bone marrow cells three times and then digested and incubated the bone fragments47,48.

For myeloid cells, cells were first stained with mouse hematopoietic lineage markers (1:600 dilution for all antibodies) including phycoerythrin (PE) anti-mouse antibodies directed against B220 (BD Bioscience, clone RA3-6B2), CD90 (BD Bioscience, clone 53-2.1), CD49b (BD Bioscience, clone DX5), NK1.1 (BD Bioscience, clone PK136) and Ter-119 (BD Bioscience, clone TER-119). This was followed by a second staining for CD45.2 (BD Bioscience, clone 104, 1:300), CD11b (BD Bioscience, clone M1/70, 1:600), CD115 (eBioscience, clone M1/70, 1:600), Ly6G (BD Bioscience, clone 1A8, 1:600), CD11c (eBioscience, clone HL3, 1:600), F4/80 (Biolegend, clone BM8, 1:600) and Ly6C (BD Bioscience, clone AL-21, 1:600). Neutrophils were identified as (CD90/B220/CD49b/NK1.1/Ter119)low(CD45.2/CD11b)highCD115lowLy6Ghigh. Monocytes were identified as (CD90/B220/CD49b/NK1.1/Ter119)lowCD11bhigh(F4/80/CD11c)lowLy-6Chigh/low or (CD45.2/CD11b)highLy6GlowCD115highLy-6Chigh/low. Macrophages were identified as (CD90/B220/CD49b/NK1.1/Ter119)lowCD11bhighLy6Clow/intLy6GlowF4/80high. For hematopoietic progenitor staining, we first incubated cells with biotin-conjugated anti-mouse antibodies (1:600 dilution for all antibodies) directed against B220 (eBioscience, clone RA3-6B2), CD11b (eBioscience, clone M1/70), CD11c (eBioscience, clone N418), NK1.1 (eBioscience, clone PK136), TER-119 (eBioscience, clone TER-119), Gr-1 (eBioscience, clone RB6-8C5), CD8a (eBioscience, clone 53-6.7), CD4 (eBioscience, clone GK1.5) and IL7R (eBioscience, clone A7R34) followed by pacific orangeconjugated streptavidin anti-biotin antibody. Then cells were stained with antibodies directed against c-Kit (BD Bioscience, clone 2B8, 1:600), Sca-1 (eBioscience, clone D7, 1:600), SLAM markers10 CD48 (eBioscience, clone HM48-1, 1:300) and CD150 (Biolegend, clone TC15-12F12.2, 1:300), CD34 (BD Bioscience, clone RAM34, 1:100), CD16/32 (BD Bioscience, clone 2.4G2, 1:600) and CD115 (eBioscience, clone AFS98, 1:600). LSKs were identified as (B220 CD11b CD11c NK1.1 Ter-119 Ly6G CD8a CD4 IL7R)lowc-KithighSca-1high. HSCs were identified as (B220 CD11b CD11c NK1.1 Ter-119 Ly6G CD8a CD4 IL7R)lowc-KithighSca-1highCD48lowCD150high. Granulocyte macrophage progenitors were defined as (B220 CD11b CD11c NK1.1 Ter-119 Ly6G CD8a CD4 IL7R)lowc-KithighSca-1low(CD34/CD16/32)highCD115int/low. Macrophage dendritic cell progenitors were defined as (B220 CD11b CD11c NK1.1 Ter-119 Ly6G CD8a CD4 IL7R)lowc-Kitint/highSca-1low(CD34/CD16/32)highCD115high. Common lymphoid progenitors were identified as (B220 CD11b CD11c NK1.1 Ter-119 Ly6G CD8a CD4)lowc-KitintSca-1intIL7Rhigh. For staining endothelial cells, we used ICAM-1 (Biolegend, clone Yn1/1.7.4, 1:300), ICAM-2 (Biolegend, clone 3C4, 1:300), VCAM-1 (Biolegend, clone 429, 1:300), E-selectin (CD62E) (BD Bioscience, clone 10E9.6, 1:100), P-selectin (CD62P) (BD Bioscience, clone RB40.34, 1:100), CD31 (Biolegend, clone 390, 1:600), CD107a (LAMP-1) (Biolegend, clone 1D4B, 1:600) and CD45.2 (Biolegend, clone 104, 1:300). Streptavidinpacific orange was used to label biotinylated antibodies. Endothelial cells were identified as CD45.2low, CD31high and CD107aintermed/high. For analysis of human monocyte subsets, cells were stained for HLA-DR (Biolegend, clone L243, 1:600), CD16 (Biolegend, clone 3G8, 1:600) and CD14 (Biolegend, clone HCD14, 1:600) after red blood cell lysis (RBC Lysis buffer, Biolegend). Monocytes were identified using forward and side scatter as well as HLA-DR. Within this population, frequencies of monocyte subsets CD14high, CD16high and CD14high/CD16high were quantified.

For BrdU pulse experiments, we used APC/FITC BrdU flow kits (BD Bioscience). One mg BrdU was injected i.p. 24 h before organ harvest. BrdU staining was performed according to the manufacturer's protocol. For BrdU application over 7 days, osmotic micropumps (Alzet) filled with 18mg BrdU were implanted. For the BrdU label-retaining pulse chase assay, BrdU was added to drinking water (1 mg/ml) for 17 days11.

After surface staining, intracellular staining was performed according to eBioscience's protocol: cells were fixed and permeabilized using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience) and then stained for the nuclear antigen Ki-67 (eBioscience, clone SolA15). Cell cycle status was determined using 4,6-diamidino-2-phenylindole (DAPI, FxCycle Violet Stain, Life Technologies).

To isolate HSPCs, we used MACS depletion columns (Miltenyi) after incubation with a cocktail of biotin-labeled antibodies (as described in the flow cytometry section) followed by incubation with streptavidin-coated microbeads (Miltenyi). Next, cells were stained with c-Kit and Sca-1, and LSKs were FACS-sorted using a FACSAria II cell sorter (BD Biosystems). To purify niche cells from hematopoietic cells, we used MACS depletion columns after incubation with a cocktail of biotin-labeled antibodies as above followed by incubation with streptavidin-coated microbeads. Cells were then stained with CD45.2, Sca-1, CD31 and CD51 (Biolegend, clone RMV-7, 1:100). Endothelial cells were identified as LinlowCD45lowSca-1highCD31high. Bone marrow MSCs were identified as LinlowCD45lowCD31lowSca-1high/intermediate and GFP+. Osteoblasts were LinlowCD45lowSca-1lowCD31lowCD51high. For adoptive transfer of GFP+ neutrophils and Ly6Chigh monocytes, bone marrow cells were collected from UBC-GFP mice for purification of neutrophils and monocytes using MACS depletion columns after incubation with a cocktail of PElabeled antibodies including B220, CD90, CD49b, NK1.1 and Ter-119 followed by an incubation with PE-coated microbeads. Aortic endothelial cells were identified as CD45.2lowCD31highCD107aint/high and FACS-sorted using a FACSAria II cell sorter.

We injected 2 106 neutrophils together with 2 106 Ly6Chigh monocytes intravenously into nonstressed and stressed Apoe/ mice (the mice were stressed for 6 weeks, and the cells were injected 2 days before the end of the 6 weeks). Aortas were harvested 48 h later. The number of CD11bhighGFP+ cells within the aorta was quantified using flow cytometry.

Aortic roots were harvested and embedded to produce 6-m sections that were stained using an anti-CD11b (BD Biosciences, clone M1/70, 1:15 dilution) or anti-Ly6G (Biolegend, clone 1A8, 1:25 dilution) antibody followed with a biotinylated secondary antibody. For color development, we used the VECTA STAIN ABC kit (Vector Laboratories, Inc.) and AEC substrate (DakoCytomation). Necrotic core and fibrous cap thickness were assessed using Masson trichrome (Sigma) staining. Necrotic core was evaluated by measuring the total acellular area within each plaque. For fibrous cap thickness, three to five measurements representing the thinnest part of the fibrous cap were averaged for each plaque as previously described49. For tyrosine hydroxylase staining, femurs were harvested and fixed in 4% paraformaldehyde for 3 h and then decalcified in 0.375 M EDTA in PBS for 10 days before paraffin embedding. Sections were cut and stained with antityrosine hydroxylase antibody (Millipore, AB152, dilution 1:100) after deparaffinization and rehydration. Sections were scanned with NanoZoomer 2.0-RS (Hamamatsu) at 40 magnification and analyzed using IPLab (Scanalytics).

For intravital microscopy of hematopoietic progenitors in the bone marrow of the calvarium, LSKs were isolated from either wild-type C57BL/6 or C57BL/6-Tg(UBC-GFP)30Scha/J mice and labeled with the lipophilic membrane dye DiD (1,1-dioctadecyl-3,3,3,3-tetramethylindodicarbocyanine perchlorate, Invitrogen). 25,000 labeled LSKs were transferred i.v. into nonirradiated C57BL/6 recipient mice. For blood pool contrast, TRITCdextran (Sigma) was injected immediately before imaging. OsteoSense 750 (PerkinElmer) was injected i.v. 24 h before in vivo imaging to outline bone structures in the calvarium50. In vivo imaging was performed on days 1 and 7 after the adoptive cell transfer using an IV100 confocal microscope (Olympus)15. Three channels were recorded (DiD excitation/emission 644/665 nm, OsteoSense 750 excitation/emission 750/780 nm, TRITCDextran excitation/emission 557/576 nm) to generate z stacks of each location at 2-m steps. Image postprocessing was performed using Image J software. Mean DiD fluorescence intensity was measured for each labeled cell and then normalized to the background by calculating the target to background ratio.

Colony-forming unit (CFU) assays were performed using a semisolid cell culture medium (Methocult M3434, Stem Cell Technology) following the manufacturer's protocol. Bones were flushed with Iscove's Modified Dulbecco's Medium (Lonza) supplemented with 2% FCS. 2 104 bone marrow cells were plated on a 35-mm plate in duplicates and incubated for 7 days. Colonies were counted using a low magnification inverted microscope.

Blood pressure and heart rate were measured using a noninvasive tail-cuff system (Kent Scientific Corporation) according to the manufacturer's instructions. For each value, the mean of three consecutive measurements was used.

Messenger RNA (mRNA) was extracted from aortic arches or bone marrow using the RNeasy Mini Kit (Qiagen) or from FACS-sorted cells using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems) according to the manufacturers' protocol. One microgram of mRNA was transcribed to complementary DNA (cDNA) with the high capacity RNA to cDNA kit (Applied Biosystems). We used Taqman primers (Applied Biosystems). Results were expressed by Ct values normalized to the housekeeping gene Gapdh.

After six weeks of stress, FMT-CT imaging was performed and compared to nonstressed, age-matched Apoe/ controls. Pan-cathepsin protease sensor (Prosense-680, PerkinElmer, 5 nmol) was injected intravenously 24 h before the imaging as previously described51.

Blood corticosterone levels were measured by ELISA (Abcam). Serum was collected between 10 a.m. and 12 p.m. For measurements of noradrenaline in the bone marrow, a 2CAT (AN) Research ELISA (Labor Diagnostika Nord) was used. One femur was snap-frozen and immediately homogenized in a catecholamine stabilizing solution containing sodium metabisulfite (4 mM), EDTA (1 mM) and hydrochloric acid (0.01 N). Prior to the ELISA, the pH of the sample was adjusted to 7.5 using sodium hydroxide (1 N). ELISAs for CXCL12 (R&D), IFN- (PBL Biomedical Laboratories) and IFN- (R&D) in the bone marrow were performed using one femur and one tibia per mouse14. ELISAs were performed according to the manufacturers' instructions.

Statistical analyses were performed using GraphPad Prism software (GraphPad Software, Inc.). Results are depicted as mean standard error of mean if not stated otherwise. For a two-group comparison, a Student's t-test was applied if the pretest for normality (D'Agostino-Pearson normality test) was not rejected at the 0.05 significance level; otherwise, a Mann-Whitney U test for nonparametric data was used. For a comparison of more than two groups, an ANOVA test, followed by a Bonferroni test for multiple comparison, was applied. For analysis of clinical data, a Wilcoxon test for matched pairs was used. P values of <0.05 indicate statistical significance. No statistical method was used to predetermine sample size.

See the article here:
Chronic variable stress activates hematopoietic stem cells ...

Posted in Massachusetts Stem Cells | Comments Off on Chronic variable stress activates hematopoietic stem cells …

Will Stem Cells Regrow You New Cartilage if You Have None …

Posted: April 11, 2019 at 1:46 am

POSTED ON 06/20/2018 IN Latest News BY Chris Centeno

I love writing about what I see day in and out. Yesterday I evaluateda patient who had been to a local West2North stem cell seminar and was told that they could regenerate cartilage in her foot. However, the joint they wanted to treat was without any cartilage and didnt hurt and caused her no functional disability. Hence, this is a great opportunity to talk about the ethical use of orthobiologics.

The idea behind stem cells is pretty cool. They can help damaged tissue heal and may be able to replace certain types of damaged tissue. Weve been using stem cells to treat joints for longer than anyone else on earth. What weve learned is that while stem cells, used in the correct way, can help get rid of the need for some invasive surgeries, they are not magic pixie dust, and theydo have limitations. One of those is that they will NOT regrow cartilage in a joint without any left. Let me explain.

There are countless animal models where stem cells, used in very specific ways, can help small holes in the cartilage heal. However, we have no research that shows that stem cells can regrow the cartilage in a joint that has severe bone on bone arthritis. This is what we have observed in the clinic as well. Meaning that we have never seen any evidence of significant cartilage growth in bone on bone arthritis regardless of which stem cell type or prep was used. To see what is and isnt possible in real MRI results with actual stem cell procedures, see my video below:

Regrettably, you got scammed! Like every good magic trick, there is always something you missed. In this case, I created a little example below of how I tilted the X-ray beam slightly and created the appearance of more joint-space width (hence more cartilage) in my knee:

Another trick often used is to inaccurately place the cursors while measuring the width of the joint. Below is an actual before and after stem cell treatment X-ray from a chiro clinic where they seem to have purposefully(or unconsciously) mismeasured the after X-ray, which makes it look like more cartilage is there, but in reality, the real width of the joint never changed. In this case, the real width of the joint is shown by the dashed lines, while the arrows point to where the chiropractor placed the cursor to measure the joint width. See what I mean below:

The treatments that are often offered at chiro clinics are amniotic or umbilical cord based. Regrettably, these tissues dont have any living and functional cells, let alone stem cells. See my video below to learn more:

My patient is an active elderly woman who developed severe arthritis in her midfoot. One joint on both sides has no cartilage. This area doesnt hurt or prevent her from doing anything. She went to a local West2North chiropractic stem cell seminar touting amniotic stem cells (really nonviable amniotic tissue) and was told they could regrow her cartilage. She then went to our local seminar and found out the opposite, so she came in to be seen. I told her that there was no way that any stem cell therapy (even a real one) would regrow cartilage in these joints, and I refused to perform a stem cell procedure.

The chiropractic clinic chain she went to was recently fined and stripped of its ability to perform stem cell injections by the attorney generals office in North Dakota because it was misrepresenting what the technology could do. In Colorado, the West2North chain was the subject of an investigative report that found many disturbing things. For example, that a nonmedical person was the one determining candidacy for these procedures.

In some severe arthritis joints that are bone on bone and are causing pain, an actual bone marrow stem cell therapy can help reduce pain and increase function without regrowing any cartilage. For example, patients with this type of knee arthritis typically do well. This can work through precise X-ray guided direct injections into the bone lesions that can cause pain in these patients or by injecting lax ligaments that are causing instability. Even just injecting specific parts of the joint sometimes will reduce inflammation for two to seven years. However, in other joints, like the hip, the success rate in severe arthritis is much lower. Hence, its critical to understand which patients can be helped and which patients should be told that this therapy is not for them.

This comment from a former patient was recently left on Facebook:

Paul Lyon- Lots of stem cell clinics have been opening up recentlyRegenexx has been around since I think 08?ask yourself before you jump into something, how many procedures have they done, how much research do they doif your going to look into stem cell therapy, do your research.Ive had both knees done 6 years ago2 orthopedic Doctors wanted to replace..im pretty much pain free. I bike, hike, ski, very active at 72.Im in Denver now, my wife just had her hip done..no surgerywe walked around Boulder the next dayall with her own stem cellsdo your research, youll end up with a trained Regenexx doctor, you wont be sorry

The upshot? Please dont get snookered into believing that an injection by a nurse in a chiropractors office will regrow you new cartilage in a bone on bone joint. That isnt going to happen. In addition, actually getting long-term results using a real stem cell procedure is difficult and requires a precise diagnosis of whats wrong and which structures should be targeted using X-ray or ultrasound guidance.

*DISCLAIMER: Like all medical procedures, Regenexx Procedures have a success and failure rate. Patient reviews and testimonials on this site should not be interpreted as a statement on the effectiveness of our treatments for anyone else. Providers listed on the Regenexx website are for informational purposes only and are not a recommendation from Regenexx for a specific provider or a guarantee of the outcome of any treatment you receive.

Read more:
Will Stem Cells Regrow You New Cartilage if You Have None ...

Posted in North Dakota Stem Cells | Comments Off on Will Stem Cells Regrow You New Cartilage if You Have None …

Stem Cell Therapy: A New Model For Health Rejuvenation …

Posted: April 11, 2019 at 1:46 am

Do you suffer from bad knees, hips rusted out, painful shoulders, bone on bone joints, Alzheimers, MS, MD, PTSD, TBI and a host of other maladies of the baby-boomer generation?

You hear conversations about it, but much of the time, youre not sure because of so much controversy in the news. These days, you cannot trust much of the news because of incredible bias by reporters, TV talk show hosts and dozens of other different filters.

Thats why Im writing this column in order to give countless Americans a chance to understand Stem Cell Therapy. At this point, doctors find that this therapy gives all of us the most advanced form of healing yet discovered on the planet. Even better, we utilize our own stem cells from a simple procedure in a doctors office.

First, a bit of history. Ive been a top-notch athlete all my life. Ive played 20 different sports such as racquetball, tennis, including 30 years of triathlons, skiing, mountain climbing, weight-lifting, bicycling and much more. Ive pounded my body, especially my knees, hips and shoulders.

When I reached 60 years of age, I played racquetball one day with the same vigor as a 21-year-old. Unfortunately, my right knee suffered an injury that never healed. It became worse and worse. When I alpine skied, it hurt. When I played tennis, it hurt. When I bicycled, it froze up and hurt. On one of my last cross continent bicycle rides in 2016, it hurt daily, it froze up and wouldnt heal. I figured my athletic days faced an abrupt ending.

When I returned home to Denver, a local pro football star, Mark Schlareth of the Denver Broncos, spoke on TV about a clinic in town that performed Stem Cell Therapy. He vouched for his renewed shoulders, hips and knees. He promised that all his pain vanished, and he had returned to a normal life. No more pills to quell the pain! He said, This procedure is quick, easy and gave me back my life.

I scheduled a free consultation the next week. If it worked for him, it might work for me.

At 9:00 a.m., I reported to the DenverRegenerativeMedicine.com office. One of the foremost medical doctors in the country, who has spoken on Ted Talks about regenerative medicine, Dr. Michael Cantor, met with me. He took X-rays of my knee. He showed where I had damaged the meniscus. He educated me as to why it wouldnt heal because of my age and the lack of blood flow.

If Im going to spend $6,000.00 out of pocket, I said. What percentage chance do I have for healing?

Dr. Cantor said, You will enjoy 99 percent healing that will give you back your knee, so you can bicycle, ski and backpack without pain. Essentially, your own stem cells will repair your knee.

Lets do it, I said.

The next Monday, I walked into the office. They took a sample of my blood to refine it into platelet rich plasma. Then, they took a syringe of my bone marrow out of my sacrum area. It took 30 seconds of slight discomfort.

From that point, they spun all the stem cells into a concentrated mass, and mixed it with the PRP, which took 30 minutes. Dr. Cantor walked back into the clinic room with a syringe.

He said, This is all you. I am reinjecting your stem cells back into your knee with the PRP, which enhances your healing at the highest level. Those stem cells will work on your knee for the next 12 to 14 months. You will start feeling the difference in the coming months. Some notice a difference in days and others within several months, depending on their injury.

I walked out of the office 90 minutes later and drove home.

What are stem cells? They equate to a re-construction, remodeling and rejuvenating work-crew that heals your damaged parts. Like, if you cut your finger, stem cells go to the cut finger and begin reconstructing it back to new. If you break a bone, the stem cells repair it.

Within two months, I didnt feel much change. But in the third month, my knee stopped hurting. I followed the physical therapists exercise protocol by pushing the stem cells to heal the knee to the demands of my athletic pursuits. Most people enjoy the pain stopping, but I wanted to return to my athletic career.

By month five, I began skiing, biking and heavy workouts in the gym. My knee performed fabulously. In the summer of 2017, I pedaled my bicycle 4,500 miles across the USA from Astoria, Oregon to Bar Harbor, Maineat the age of 70. My book about the ride published in January 2019: Old Men Bicycling Across America: A Journey Beyond Old Age.

What else do stem cells accomplish? The research shows that stem cell therapy now finds incredible advancements in healing or dramatically improving COPD, Parkinsons Disease, Multiple Sclerosis, Alzheimers, PTSD, LUPUS, Crohns, TBI, arthritis and many more maladies. Some studies show it works on cancer.

They obtain your own stem cells from your own bone marrow, or, they obtain it from your own fat cells through mini-liposuction. They can also harvest stem cells from the umbilical cord of a new born baby. After the baby arrives, they cut the umbilical cord and place it into a sterile package for processing. Once its certified, you can use it with all its very young stem cells for maximum healing.

You might watch this nine-part series which interviews numerous doctors who perform the procedure across the USA. Over 100 clinics now operate. This series presents you with all the information you need to make some choices for your health and those of your loved ones:

The Healing Miracle: the truth about stem cellsby Jeff Hayes Films

Also,in Florida, Dr. Kristen Comellaworks on stem cell face lifts, joints, skin, PD, MD, MS, and much more.

Another clinic with Dr. Tami Maragelia in Seattle, Washington.

In California, Dr. Mark Berman, plastic surgeon and face lift expert who performs stem cell face lifts.

You can find clinics in Michigan, New York, Denver, Atlanta, Dallas and many more states.

You can call them for a consultation over the phone. Watch the Jeff Hayes series first, so you can glean all you need to know and create questions for the clinics.

Finally, stem cell therapy offers baby-boomers a new lease on life, a wonderful method for avoiding chronic pain, dementia and many other diseases of old age. Stem cell therapy provides the greatest advancement in human health renewal, ever, in the history of the world.

Take advantage of it; I did, and I am eternally grateful. I was so thankful to be able to pedal my bike across the continent that I began crying at different moments last summer because my mind felt grateful for the miracle of stem cell healing. What am I doing this week? Going bump skiing in the Rocky Mountains! This summer, bicycling the Continental Divide from Mexico to Canada. This kid doesnt waste a second with my healthy knees and the open road beckoning with adventure.

2019 NWV All Rights Reserved

E-Mail Frosty: [emailprotected]

More:
Stem Cell Therapy: A New Model For Health Rejuvenation ...

Posted in New Mexico Stem Cells | Comments Off on Stem Cell Therapy: A New Model For Health Rejuvenation …

genetic engineering – Kids | Britannica Kids | Homework Help

Posted: April 11, 2019 at 1:44 am

In genetic engineering, scientists combine fragments, or parts, of DNA from different organisms. One way they do this is by cutting and rejoining genes. First, they take DNA from one organism, called the donor, and cut out the gene that they want to use. Next, they join that gene with the DNA of another organism. The result is DNA that has traits of both organisms. This new DNA is called recombinant DNA.

To make more copies of recombinant DNA, scientists may place it inside bacteria. When the bacteria reproduces, the DNA also is reproduced. This process is called gene cloning.

There are several ways to produce a fully grown plant or animal that contains recombinant DNA. Bacteria carrying the DNA may be allowed to infect plant cells. The cells then develop into plants with traits of both original organisms. Recombinant DNA also may be injected into the egg cells of animals. The eggs then grow into animals with the desired traits.

More here:
genetic engineering - Kids | Britannica Kids | Homework Help

Posted in Genetic Engineering | Comments Off on genetic engineering – Kids | Britannica Kids | Homework Help

Page 1,377«..1020..1,3761,3771,3781,379..1,3901,400..»